Compare · ASXC vs RMD
ASXC vs RMD
Side-by-side comparison of Asensus Surgical Inc. (ASXC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASXC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 169.7x ASXC ($201.1M).
- RMD has hit the wire 9 times in the past 4 weeks while ASXC has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 3 for ASXC).
- Company
- Asensus Surgical Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $201.1M
- $34.13B
- 1M return
- -
- +16.50%
- 1Y return
- -
- -17.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 0
- 9
- Recent ratings
- 3
- 25
Asensus Surgical Inc.
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ASXC
- SEC Form 15-12G filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form EFFECT filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
- SEC Form S-8 POS filed by Asensus Surgical Inc.
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)